IL-13 Zetakine Transgenic CTLs to Kill Glioblastoma Cells in vivo in
the Presence of Immunosuppressing Glucocorticoids" Philip Gregory, D.
Phil., Vice President, Research, Sangamo BioSciences, Inc.
-- Monday, May 19:
-- Workshop: "Emerging Technologies" Bruce Levine, Ph.D., Department
of Pathology and Laboratory Medicine, University of Pennsylvania
School of Medicine.
-- Poster Session: "Controlling HIV in vivo - Establishment of HIV
Resistant CD4 T Cells by Engineered Zinc Finger Protein
Sangamo BioSciences, Inc. is focused on the research and development of
novel DNA-binding proteins for therapeutic gene regulation and
modification. The most advanced ZFP Therapeutic(TM) development program is
currently in Phase 2 clinical trials for evaluation of safety and clinical
effect in patients with diabetic neuropathy. Phase 1 clinical trials are
ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other
therapeutic development programs are focused on cancer and HIV/AIDS,
neuropathic pain, nerve regeneration, Parkinson's disease and monogenic
diseases. Sangamo's core competencies enable the engineering of a class of
DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By
engineering ZFPs that recognize a specific DNA sequence Sangamo has created
ZFP transcription factors (ZFP TF)(TM) that can control gene expression
and, consequently, cell function. Sangamo is also developing
sequence-specific ZFP Nucleases (ZFN)(TM) for gene modification. Sangamo
has established strategic partnerships with companies outside of the human
therapeutic space including Dow AgroSciences, Sigma-Aldrich Corporation and
several companies applying its ZFP Technology to enhance the production of
protein pharmaceuticals. For more information about Sangamo, visit the
company's web site at '/>"/>
|SOURCE Sangamo BioSciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved